Azitra Inc (AZTR)

$0.17 +0.00 (2.03%)
Market Cap 1.80M
Revenue (ttm) 10,000.00
Net Income (ttm) -8.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,700.00%
Debt to Equity Ratio 0.00
Volume 1,242,500
Avg Vol 1,326,500
Day's Range N/A - N/A
Shares Out 10.74M
Stochastic %K 24%
Beta -1.59
Analysts Strong Sell
Price Target $2.70

Company Profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular ras...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 646 6446
Address:
21 Business Park Drive, Branford, United States
Buyredselgreen
Buyredselgreen Feb. 24 at 2:20 AM
$AZTR
0 · Reply
marinax
marinax Feb. 23 at 8:57 PM
$AZTR need 0.30$ to break even . 😢😢
1 · Reply
Easttenn988
Easttenn988 Feb. 23 at 6:30 PM
$AZTR Dips are awesome 👏
1 · Reply
fisher04
fisher04 Feb. 23 at 4:52 PM
$AZTR added more .
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 4:39 PM
$AZTR Beautiful dip here below .17. Anything under .20
1 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 4:28 PM
$AZTR I keep adding; won't be long now
0 · Reply
aaa31
aaa31 Feb. 23 at 4:06 PM
$AZTR bought some. Will watch for catalyst in a week
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 3:32 PM
$YMAT Were you with me? Still accumulating $AZTR and waiting for $CHOW (enter below .61). Watching $ROLR to take a spot, just not yet
2 · Reply
Easttenn988
Easttenn988 Feb. 23 at 2:43 PM
$AZTR yup in here always great calls 💯 👇
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 9:55 AM
$AZTR Bottom with catalyst: What were $SGN people doing in November when this was .11??? who cares, they're chasing it now, instead of being in at the bottom.
0 · Reply
Latest News on AZTR
Azitra, Inc. to Present at BIO Investment & Growth Summit

Feb 19, 2026, 8:00 AM EST - 4 days ago

Azitra, Inc. to Present at BIO Investment & Growth Summit

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Feb 6, 2026, 4:15 PM EST - 17 days ago

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Dec 17, 2025, 4:10 PM EST - 2 months ago

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Nov 24, 2025, 9:00 AM EST - 3 months ago

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Nov 12, 2025, 5:15 PM EST - 3 months ago

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Azitra, Inc. Addresses False Report Regarding Sale of Securities

Nov 7, 2025, 6:00 AM EST - 3 months ago

Azitra, Inc. Addresses False Report Regarding Sale of Securities

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

Oct 20, 2025, 8:02 AM EDT - 4 months ago

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

Azitra Receives Notice of Non-Compliance from NYSE American

Oct 3, 2025, 4:45 PM EDT - 5 months ago

Azitra Receives Notice of Non-Compliance from NYSE American

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:10 AM EDT - 6 months ago

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Aug 27, 2025, 8:10 AM EDT - 6 months ago

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus

Aug 22, 2025, 6:01 AM EDT - 6 months ago

Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus

IVV SPXL SPY SSO UPRO VOO ZM

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Aug 11, 2025, 5:00 PM EDT - 7 months ago

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Azitra, Inc. Announces Reverse Stock Split

Aug 11, 2025, 4:15 PM EDT - 7 months ago

Azitra, Inc. Announces Reverse Stock Split

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Jun 17, 2025, 8:02 AM EDT - 8 months ago

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Jun 10, 2025, 8:33 AM EDT - 9 months ago

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

May 28, 2025, 8:33 AM EDT - 9 months ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

May 14, 2025, 4:05 PM EDT - 10 months ago

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

May 13, 2025, 5:06 PM EDT - 10 months ago

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 25, 2025, 8:33 AM EDT - 10 months ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Apr 24, 2025, 4:05 PM EDT - 10 months ago

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Azitra to Present at Microbiome Times Partnering Forum

Mar 12, 2025, 8:33 AM EDT - 1 year ago

Azitra to Present at Microbiome Times Partnering Forum

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:30 AM EST - 1 year ago

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Feb 4, 2025, 2:20 PM EST - 1 year ago

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Feb 3, 2025, 9:05 AM EST - 1 year ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Azitra, Inc. to Present at The Microcap Conference

Jan 27, 2025, 4:05 PM EST - 1 year ago

Azitra, Inc. to Present at The Microcap Conference

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Jan 15, 2025, 8:30 AM EST - 1 year ago

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Azitra Announces Proposed Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 1 year ago

Azitra Announces Proposed Public Offering of Common Stock

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Nov 12, 2024, 5:05 PM EST - 1 year ago

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Azitra to Present at BIO-Europe 2024

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Azitra to Present at BIO-Europe 2024

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 11, 2024, 9:00 AM EDT - 1 year ago

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Sep 18, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 20, 2024, 4:15 PM EDT - 1 year ago

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 6:23 PM EDT - 1 year ago

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Jul 25, 2024, 5:57 PM EDT - 1 year ago

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

Jul 25, 2024, 1:54 PM EDT - 1 year ago

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

HAL

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

Jul 25, 2024, 1:13 PM EDT - 1 year ago

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

HAL

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Jul 23, 2024, 9:20 PM EDT - 1 year ago

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

May 31, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

May 17, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

May 10, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

May 9, 2024, 5:00 PM EDT - 1 year ago

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Apr 18, 2024, 4:15 PM EDT - 2 years ago

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 15, 2024, 4:15 PM EDT - 2 years ago

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Buyredselgreen
Buyredselgreen Feb. 24 at 2:20 AM
$AZTR
0 · Reply
marinax
marinax Feb. 23 at 8:57 PM
$AZTR need 0.30$ to break even . 😢😢
1 · Reply
Easttenn988
Easttenn988 Feb. 23 at 6:30 PM
$AZTR Dips are awesome 👏
1 · Reply
fisher04
fisher04 Feb. 23 at 4:52 PM
$AZTR added more .
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 4:39 PM
$AZTR Beautiful dip here below .17. Anything under .20
1 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 4:28 PM
$AZTR I keep adding; won't be long now
0 · Reply
aaa31
aaa31 Feb. 23 at 4:06 PM
$AZTR bought some. Will watch for catalyst in a week
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 3:32 PM
$YMAT Were you with me? Still accumulating $AZTR and waiting for $CHOW (enter below .61). Watching $ROLR to take a spot, just not yet
2 · Reply
Easttenn988
Easttenn988 Feb. 23 at 2:43 PM
$AZTR yup in here always great calls 💯 👇
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 9:55 AM
$AZTR Bottom with catalyst: What were $SGN people doing in November when this was .11??? who cares, they're chasing it now, instead of being in at the bottom.
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 2:24 AM
$AZTR whoever the dummy; doing a market sell, you'll be chasing. Presentation Mar 2nd/ topline data imminent/ this is the bottom, set up is good to go
2 · Reply
BlackSoul
BlackSoul Feb. 23 at 1:12 AM
$AZTR 👀👀👀 0.1980s
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 23 at 12:17 AM
$AZTR ATR-12 — In Phase 1b for Netherton syndrome (rare skin disorder with no approved treatments). Recent updates show promising safety data, patient dosing/enrollment progress, and topline efficacy potentially in early 2026. ATR-04 — Phase 1/2 for EGFR inhibitor-associated rash in cancer patients (common side effect). First patient dosed, Fast Track designation from FDA. ATR-01 — Preclinical/IND-enabling for ichthyosis vulgaris.
0 · Reply
KimberleyAnn
KimberleyAnn Feb. 22 at 11:48 PM
$AZTR
0 · Reply
fisher04
fisher04 Feb. 22 at 7:21 PM
$AZTR I have checked your profile not impressive information and predictions. always do your dd before buying any stock. we know big data ahead it should and will spike in coming days why so kuch negativity. @KimberleyAnn , @ProfessorDman1 @BlackSoul and some others already loaded .
0 · Reply
aafetygod
aafetygod Feb. 22 at 5:53 AM
$AZTR If this doesn't make a big move next week, it'll run the week after. Stocks like this usually don't do a full 100% run; they tend to pump like 50-70%. The chart doesn't look like it'll drop below 0.15, but if it does dip under that, it'll probably hit the low 0.10s, right? After that, it'll pump to around 0.20 and then do an RS or get delisted.
1 · Reply
fisher04
fisher04 Feb. 21 at 7:15 PM
$AZTR big days ahead . hope it will climb to 0.25- 0.30$ before data and boom .
0 · Reply
marinax
marinax Feb. 21 at 3:07 AM
$AZTR what is pt after positive data release?
1 · Reply
KimberleyAnn
KimberleyAnn Feb. 20 at 11:04 PM
$AZTR $SGN $CHOW Beautiful SGN; now aztr and chow. Also $ENSC I took a starter here! Hope you're with me!
0 · Reply
Universelaw
Universelaw Feb. 20 at 9:51 PM
$AZTR
0 · Reply
pbacher
pbacher Feb. 20 at 9:03 PM
$AZTR the daily chart looks really horrible
0 · Reply
pbacher
pbacher Feb. 20 at 7:56 PM
$AZTR and i averaged down. Well, well, well...
0 · Reply